NasdaqGM:OCULPharmaceuticals
Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Phase 3 SOL-1 Data Draws Fresh Investor Focus
Ocular Therapeutix (OCUL) is drawing fresh attention as investors look ahead to upcoming April conferences, where the company plans to share additional analyses from its pivotal Phase 3 SOL-1 trial of AXPAXLI.
See our latest analysis for Ocular Therapeutix.
At a share price of US$8.49, Ocular Therapeutix has seen a 1-day share price return of 1.92% and 7-day share price return of 5.20%. The 30-day share price return of 21.10% and year to date share price return of 28.17% are being considered...